• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Septerna Inc.

    5/15/25 4:37:36 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SEPN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Septerna, Inc.

    (Name of Issuer)


    Common Stock, $0.001 par value per share

    (Title of Class of Securities)


    81734D104

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    81734D104


    1Names of Reporting Persons

    BIOTECHNOLOGY VALUE FUND L P
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,299,671.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,299,671.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,299,671.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.2 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    81734D104


    1Names of Reporting Persons

    BVF I GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,299,671.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,299,671.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,299,671.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.2 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    81734D104


    1Names of Reporting Persons

    BIOTECHNOLOGY VALUE FUND II LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,804,322.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,804,322.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,804,322.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.1 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    81734D104


    1Names of Reporting Persons

    BVF II GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,804,322.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,804,322.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,804,322.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.1 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    81734D104


    1Names of Reporting Persons

    Biotechnology Value Trading Fund OS LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    233,426.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    233,426.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    233,426.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.5 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    81734D104


    1Names of Reporting Persons

    BVF Partners OS Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    233,426.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    233,426.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    233,426.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.5 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    81734D104


    1Names of Reporting Persons

    BVF GP HOLDINGS LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,103,993.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,103,993.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,103,993.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.2 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    81734D104


    1Names of Reporting Persons

    BVF PARTNERS L P/IL
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,396,124.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,396,124.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,396,124.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IA, PN


    SCHEDULE 13G

    CUSIP No.
    81734D104


    1Names of Reporting Persons

    BVF INC/IL
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,396,124.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,396,124.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,396,124.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    81734D104


    1Names of Reporting Persons

    LAMPERT MARK N
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,396,124.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,396,124.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,396,124.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Septerna, Inc.
    (b)Address of issuer's principal executive offices:

    Item 2. 
    (a)Name of person filing:

    Biotechnology Value Fund, L.P. ("BVF") BVF I GP LLC ("BVF GP") Biotechnology Value Fund II, L.P. ("BVF2") BVF II GP LLC ("BVF2 GP") Biotechnology Value Trading Fund OS LP ("Trading Fund OS") BVF Partners OS Ltd. ("Partners OS") BVF GP Holdings LLC ("BVF GPH") BVF Partners L.P. ("Partners") BVF Inc. Mark N. Lampert ("Mr. Lampert") Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."
    (b)Address or principal business office or, if none, residence:

    Biotechnology Value Fund, L.P. 44 Montgomery St., 40th Floor San Francisco, California 94104 BVF I GP LLC 44 Montgomery St., 40th Floor San Francisco, California 94104 Biotechnology Value Fund II, L.P. 44 Montgomery St., 40th Floor San Francisco, California 94104 BVF II GP LLC 44 Montgomery St., 40th Floor San Francisco, California 94104 Biotechnology Value Trading Fund OS LP PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands BVF Partners OS Ltd. PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands BVF GP Holdings LLC 44 Montgomery St., 40th Floor San Francisco, California 94104 BVF Partners L.P. 44 Montgomery St., 40th Floor San Francisco, California 94104 BVF Inc. 44 Montgomery St., 40th Floor San Francisco, California 94104 Mark N. Lampert 44 Montgomery St., 40th Floor San Francisco, California 94104
    (c)Citizenship:

    Biotechnology Value Fund, L.P. Delaware BVF I GP LLC Delaware Biotechnology Value Fund II, L.P. Delaware BVF II GP LLC Delaware Biotechnology Value Trading Fund OS LP Cayman Islands BVF Partners OS Ltd. Cayman Islands BVF GP Holdings LLC Delaware BVF Partners L.P. Delaware BVF Inc. Delaware Mark N. Lampert United States
    (d)Title of class of securities:

    Common Stock, $0.001 par value per share
    (e)CUSIP No.:

    81734D104
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    As of the close of business on March 31, 2025, (i) BVF beneficially owned 2,299,671 Shares, (ii) BVF2 beneficially owned 1,804,322 Shares and (iii) Trading Fund OS beneficially owned 233,426 Shares. BVF GP, as the general partner of BVF, may be deemed to beneficially own the 2,299,671 Shares beneficially owned by BVF. BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 1,804,322 Shares beneficially owned by BVF2. Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 233,426 Shares beneficially owned by Trading Fund OS. BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 4,103,993 Shares beneficially owned in the aggregate by BVF and BVF2. Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 4,396,124 Shares beneficially owned in the aggregate by BVF, BVF2 and Trading Fund OS and held in a certain Partners managed account (the "Partners Managed Account"), including 58,705 Shares held in the Partners Managed Account. BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 4,396,124 Shares beneficially owned by Partners. Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 4,396,124 Shares beneficially owned by BVF Inc. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Shares beneficially owned by BVF2. Partners OS disclaims beneficial ownership of the Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.
    (b)Percent of class:

    The following percentages are based on 44,442,496 Shares outstanding as of March 17, 2025, as reported in the Issuer's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 27, 2025. As of the close of business on March 31, 2025, (i) BVF beneficially owned approximately 5.2% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 4.1% of the outstanding Shares, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding Shares, (iv) BVF GP may be deemed to beneficially own approximately 5.2% of the outstanding Shares, (v) BVF2 GP may be deemed to beneficially own approximately 4.1% of the outstanding Shares, (vi) Partners OS may be deemed to beneficially own less than 1% of the outstanding Shares, (vii) BVF GPH may be deemed to beneficially own approximately 9.2% of the outstanding Shares, and (viii) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 9.9% of the outstanding Shares (less than 1% of the outstanding Shares are held in the Partners Managed Account).
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Cover Pages Items 5-9.

     (ii) Shared power to vote or to direct the vote:

    See Cover Pages Items 5-9.

     (iii) Sole power to dispose or to direct the disposition of:

    See Cover Pages Items 5-9.

     (iv) Shared power to dispose or to direct the disposition of:

    See Cover Pages Items 5-9.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    BVF GP, BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF. BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF2. Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by Trading Fund OS and held in the Partners Managed Account.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit 99.1 to the Schedule 13G filed with the Securities and Exchange Commission on November 1, 2024.
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    BIOTECHNOLOGY VALUE FUND L P
     
    Signature:/s/ Mark N. Lampert
    Name/Title:Mark N. Lampert, Authorized Signatory
    Date:05/15/2025
     
    BVF I GP LLC
     
    Signature:/s/ Mark N. Lampert
    Name/Title:Mark N. Lampert, Authorized Signatory
    Date:05/15/2025
     
    BIOTECHNOLOGY VALUE FUND II LP
     
    Signature:/s/ Mark N. Lampert
    Name/Title:Mark N. Lampert, Authorized Signatory
    Date:05/15/2025
     
    BVF II GP LLC
     
    Signature:/s/ Mark N. Lampert
    Name/Title:Mark N. Lampert, Authorized Signatory
    Date:05/15/2025
     
    Biotechnology Value Trading Fund OS LP
     
    Signature:/s/ Mark N. Lampert
    Name/Title:Mark N. Lampert, Authorized Signatory
    Date:05/15/2025
     
    BVF Partners OS Ltd.
     
    Signature:/s/ Mark N. Lampert
    Name/Title:Mark N. Lampert, Authorized Signatory
    Date:05/15/2025
     
    BVF GP HOLDINGS LLC
     
    Signature:/s/ Mark N. Lampert
    Name/Title:Mark N. Lampert, Authorized Signatory
    Date:05/15/2025
     
    BVF PARTNERS L P/IL
     
    Signature:/s/ Mark N. Lampert
    Name/Title:Mark N. Lampert, Authorized Signatory
    Date:05/15/2025
     
    BVF INC/IL
     
    Signature:/s/ Mark N. Lampert
    Name/Title:Mark N. Lampert, Authorized Signatory
    Date:05/15/2025
     
    LAMPERT MARK N
     
    Signature:/s/ Mark N. Lampert
    Name/Title:Mark N. Lampert
    Date:05/15/2025
    Get the next $SEPN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SEPN

    DatePrice TargetRatingAnalyst
    6/23/2025$26.00Buy
    H.C. Wainwright
    2/18/2025$14.00Overweight → Equal Weight
    Wells Fargo
    11/19/2024$38.00Overweight
    Analyst
    11/19/2024Buy
    TD Cowen
    11/19/2024$43.00Overweight
    Wells Fargo
    11/19/2024$50.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $SEPN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Septerna with a new price target

    H.C. Wainwright initiated coverage of Septerna with a rating of Buy and set a new price target of $26.00

    6/23/25 8:09:11 AM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Septerna downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Septerna from Overweight to Equal Weight and set a new price target of $14.00

    2/18/25 8:55:10 AM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Analyst initiated coverage on Septerna with a new price target

    Analyst initiated coverage of Septerna with a rating of Overweight and set a new price target of $38.00

    11/19/24 7:39:27 AM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SEPN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Septerna to Participate in Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following upcoming investor conferences in September: Cantor Global Healthcare Conference 2025 Presentation on Wednesday, September 3, 2025, at 11:30 a.m. ET 2025 Wells Fargo Healthcare ConferenceFireside chat on Friday, September 5, 2025, at 8:45 a.m. ET Live webcasts of the presentations will be available in the investors section of the company's website at www.septerna.com. Replays will be archived for at least 30 days f

    8/27/25 8:00:00 AM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases

    SOUTH SAN FRANCISCO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the dosing of the first participants in its Phase 1 clinical trial of SEP-631, a selective oral small molecule Mas-related G protein-coupled receptor X2 (MRGPRX2) negative allosteric modulator (NAM) being developed for the treatment of chronic spontaneous urticaria (CSU) and other mast cell-driven diseases. The Phase 1 single-ascending dose (SAD) and multiple-ascending dose (MAD) clinical trial will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodyna

    8/21/25 8:00:00 AM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results

    Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development Initiating Phase 1 Trial for SEP-631, MRGPRX2 NAM Program, for Mast Cell Diseases Updated Cash Runway Expected to Support Operating Plans at Least into 2029 SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted key business updates and upcoming milestones and reported financial results for the second quarter ended June 30, 2025.   "We are executing effectively across our portfolio, with each program nearing important milestones," said Je

    8/11/25 4:01:00 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SEPN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ezekowitz Alan bought $92,270 worth of shares (13,319 units at $6.93), increasing direct ownership by 13% to 117,420 units (SEC Form 4)

    4 - Septerna, Inc. (0001984086) (Issuer)

    3/10/25 4:18:19 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ezekowitz Alan bought $515,934 worth of shares (86,681 units at $5.95), increasing direct ownership by 498% to 104,101 units (SEC Form 4)

    4 - Septerna, Inc. (0001984086) (Issuer)

    3/6/25 9:02:51 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and President Finer Jeffrey bought $96,961 worth of shares (17,000 units at $5.70), increasing direct ownership by 2% to 771,907 units (SEC Form 4)

    4 - Septerna, Inc. (0001984086) (Issuer)

    2/27/25 6:53:01 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SEPN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Biological Sciences Klein Uwe exercised 23,008 shares at a strike of $4.10 (SEC Form 4)

    4 - Septerna, Inc. (0001984086) (Issuer)

    8/19/25 5:02:20 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief People Officer Shaikhly Samira

    4 - Septerna, Inc. (0001984086) (Issuer)

    8/11/25 7:11:23 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by President and COO Bhatt Elizabeth

    4 - Septerna, Inc. (0001984086) (Issuer)

    8/11/25 7:09:59 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SEPN
    SEC Filings

    View All

    Septerna Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Septerna, Inc. (0001984086) (Filer)

    9/3/25 7:00:21 AM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Septerna Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Septerna, Inc. (0001984086) (Filer)

    8/21/25 8:33:01 AM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Septerna Inc.

    10-Q - Septerna, Inc. (0001984086) (Filer)

    8/11/25 4:11:42 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SEPN
    Leadership Updates

    Live Leadership Updates

    View All

    Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer

    SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotech company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Gil Labrucherie, CFA, J.D., as Chief Financial Officer. Mr. Labrucherie is a seasoned biopharma executive with more than 25 years of senior leadership experience in finance and legal roles for public biopharmaceutical and technology companies. "We are excited to welcome Gil to the team," said Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna. "His extensive expertise leading public company finance and capital strategy will be ins

    1/6/25 7:00:00 AM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SEPN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Septerna Inc.

    SC 13D - Septerna, Inc. (0001984086) (Subject)

    11/4/24 4:39:38 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Septerna Inc.

    SC 13G - Septerna, Inc. (0001984086) (Subject)

    11/4/24 4:15:38 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Septerna Inc.

    SC 13G - Septerna, Inc. (0001984086) (Subject)

    11/1/24 4:27:45 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care